IP Library › Patent Application 16285741
Patent Application
App. No. 16/285,741

Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/285,741
Abstract

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

Claims (10)

1 - 38 . (canceled)

39 . A method of increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells.

40 . The method of claim 39 , wherein the composition comprises a MASP-1 inhibitory agent.

41 . The method of claim 39 , wherein the composition comprises a MASP-3 inhibitory agent.

42 . The method of claim 39 , wherein the composition comprises a MASP-1 inhibitory agent and a MASP-3 inhibitory agent.

43 . The method of claim 39 , further comprising administering to the subject a composition comprising a MASP-2 inhibitory agent.

44 . The method of claim 40 , wherein the MASP-1 inhibitory agent is a MASP-1 monoclonal antibody.

45 . The method of claim 41 , wherein the MASP-3 inhibitory agent is a MASP-3 monoclonal antibody.

46 . The method of claim 43 , wherein the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody.

47 - 92 . (canceled)